John Tentler
Concepts (387)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pyrimidines | 8 | 2020 | 376 | 1.620 |
Why?
| Xenograft Model Antitumor Assays | 21 | 2020 | 698 | 1.420 |
Why?
| Triple Negative Breast Neoplasms | 5 | 2020 | 157 | 1.400 |
Why?
| Protein Kinase Inhibitors | 15 | 2020 | 785 | 1.390 |
Why?
| Antineoplastic Agents | 18 | 2019 | 1879 | 1.300 |
Why?
| Colorectal Neoplasms | 11 | 2018 | 615 | 1.130 |
Why?
| Proto-Oncogene Proteins | 10 | 2018 | 608 | 1.000 |
Why?
| Azepines | 4 | 2020 | 75 | 0.920 |
Why?
| Piperazines | 4 | 2020 | 309 | 0.910 |
Why?
| Pyrazoles | 4 | 2018 | 362 | 0.860 |
Why?
| Melanoma | 10 | 2018 | 620 | 0.860 |
Why?
| Quinoxalines | 2 | 2020 | 60 | 0.860 |
Why?
| Gene Expression Regulation, Neoplastic | 9 | 2020 | 1141 | 0.840 |
Why?
| Mice, Nude | 16 | 2020 | 630 | 0.730 |
Why?
| Cell Proliferation | 21 | 2020 | 2186 | 0.690 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 111 | 0.680 |
Why?
| beta Catenin | 2 | 2020 | 219 | 0.670 |
Why?
| Enoyl-CoA Hydratase | 1 | 2018 | 9 | 0.640 |
Why?
| DNA-Binding Proteins | 8 | 2015 | 1314 | 0.600 |
Why?
| Cell Line, Tumor | 24 | 2020 | 2710 | 0.600 |
Why?
| Tumor Microenvironment | 1 | 2020 | 430 | 0.590 |
Why?
| Benzimidazoles | 4 | 2013 | 138 | 0.550 |
Why?
| Mutation | 11 | 2018 | 3345 | 0.540 |
Why?
| Cardiomyopathy, Dilated | 1 | 2018 | 348 | 0.510 |
Why?
| Tumor Suppressor Proteins | 2 | 2015 | 282 | 0.500 |
Why?
| Tumor Suppressor Protein p53 | 4 | 2016 | 445 | 0.500 |
Why?
| Genomics | 1 | 2018 | 635 | 0.460 |
Why?
| ras Proteins | 3 | 2013 | 138 | 0.450 |
Why?
| Pyrazines | 5 | 2013 | 71 | 0.440 |
Why?
| Proto-Oncogene Proteins B-raf | 4 | 2018 | 192 | 0.410 |
Why?
| Apoptosis | 13 | 2020 | 2362 | 0.400 |
Why?
| Oncogene Proteins, Fusion | 3 | 2018 | 179 | 0.390 |
Why?
| Biomarkers, Tumor | 3 | 2017 | 1040 | 0.380 |
Why?
| Mice | 21 | 2020 | 14863 | 0.380 |
Why?
| Drug Design | 1 | 2012 | 148 | 0.370 |
Why?
| Nuclear Proteins | 1 | 2015 | 591 | 0.360 |
Why?
| Prolactin | 7 | 2004 | 96 | 0.350 |
Why?
| Drug Resistance, Neoplasm | 8 | 2020 | 636 | 0.350 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2010 | 113 | 0.350 |
Why?
| Histone Deacetylase Inhibitors | 3 | 2022 | 198 | 0.340 |
Why?
| Aurora Kinase A | 4 | 2020 | 51 | 0.340 |
Why?
| Animals | 44 | 2020 | 31698 | 0.320 |
Why?
| Neoplasms | 4 | 2022 | 2097 | 0.310 |
Why?
| Cell Transformation, Neoplastic | 4 | 2013 | 308 | 0.290 |
Why?
| Imidazoles | 4 | 2013 | 208 | 0.290 |
Why?
| Pituitary Gland | 7 | 2003 | 148 | 0.280 |
Why?
| Ethanol | 11 | 1997 | 538 | 0.270 |
Why?
| Gene Expression Profiling | 6 | 2018 | 1518 | 0.270 |
Why?
| Hydroxamic Acids | 3 | 2011 | 80 | 0.260 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2020 | 1355 | 0.260 |
Why?
| Exome | 2 | 2017 | 200 | 0.250 |
Why?
| Breast Neoplasms | 3 | 2012 | 1862 | 0.250 |
Why?
| Ubiquitin-Activating Enzymes | 2 | 2016 | 13 | 0.240 |
Why?
| Transcription Factors | 4 | 2011 | 1528 | 0.240 |
Why?
| Pyrimidinones | 2 | 2015 | 88 | 0.240 |
Why?
| Pyridones | 2 | 2015 | 123 | 0.230 |
Why?
| Receptor, IGF Type 1 | 3 | 2013 | 58 | 0.220 |
Why?
| Humans | 44 | 2022 | 114662 | 0.220 |
Why?
| Cell Cycle Proteins | 3 | 2018 | 551 | 0.210 |
Why?
| Hypothalamus | 12 | 1997 | 147 | 0.200 |
Why?
| Immunoblotting | 5 | 2015 | 283 | 0.200 |
Why?
| Female | 27 | 2020 | 59493 | 0.190 |
Why?
| Drug Synergism | 4 | 2018 | 316 | 0.190 |
Why?
| Tumor Cells, Cultured | 3 | 2020 | 849 | 0.190 |
Why?
| c-Mer Tyrosine Kinase | 2 | 2018 | 43 | 0.180 |
Why?
| Transcription, Genetic | 4 | 2013 | 1313 | 0.180 |
Why?
| G2 Phase Cell Cycle Checkpoints | 3 | 2018 | 41 | 0.180 |
Why?
| Signal Transduction | 10 | 2018 | 4512 | 0.180 |
Why?
| Benzoxazoles | 1 | 2020 | 16 | 0.180 |
Why?
| Breast | 3 | 2018 | 139 | 0.170 |
Why?
| Wnt Signaling Pathway | 2 | 2019 | 146 | 0.170 |
Why?
| Boronic Acids | 2 | 2011 | 33 | 0.170 |
Why?
| Epithelial Cells | 4 | 2011 | 950 | 0.170 |
Why?
| Growth Hormone | 3 | 1997 | 103 | 0.170 |
Why?
| Sequence Analysis, RNA | 2 | 2018 | 385 | 0.170 |
Why?
| eIF-2 Kinase | 1 | 2019 | 24 | 0.170 |
Why?
| Proto-Oncogene Proteins p21(ras) | 4 | 2016 | 228 | 0.160 |
Why?
| Cell Cycle | 7 | 2018 | 542 | 0.160 |
Why?
| Breast Neoplasms, Male | 1 | 2018 | 28 | 0.150 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2018 | 108 | 0.150 |
Why?
| Linkage Disequilibrium | 1 | 2018 | 245 | 0.150 |
Why?
| MAP Kinase Kinase Kinases | 2 | 2015 | 68 | 0.150 |
Why?
| Septins | 1 | 2018 | 40 | 0.150 |
Why?
| Mice, Inbred BALB C | 1 | 2020 | 1143 | 0.150 |
Why?
| Drug Therapy, Combination | 1 | 2020 | 951 | 0.150 |
Why?
| Cytoskeleton | 1 | 2018 | 176 | 0.140 |
Why?
| Genetics, Population | 1 | 2018 | 188 | 0.140 |
Why?
| Gonadotropin-Releasing Hormone | 8 | 1993 | 188 | 0.140 |
Why?
| Neurofibromin 1 | 1 | 2017 | 22 | 0.140 |
Why?
| Somatostatin | 1 | 1997 | 52 | 0.140 |
Why?
| Armadillo Domain Proteins | 1 | 2017 | 5 | 0.140 |
Why?
| Gene Regulatory Networks | 1 | 2018 | 228 | 0.140 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2017 | 63 | 0.140 |
Why?
| Adenine | 1 | 2018 | 219 | 0.140 |
Why?
| Testis | 2 | 1997 | 133 | 0.140 |
Why?
| RNA Splicing Factors | 1 | 2017 | 49 | 0.140 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2017 | 25 | 0.140 |
Why?
| Cyclopentanes | 1 | 2016 | 15 | 0.140 |
Why?
| Sexual Maturation | 1 | 1997 | 47 | 0.140 |
Why?
| Inhibitory Concentration 50 | 2 | 2016 | 74 | 0.140 |
Why?
| Cyclic AMP Response Element-Binding Protein | 1 | 1997 | 127 | 0.140 |
Why?
| Mucous Membrane | 1 | 2017 | 108 | 0.140 |
Why?
| RNA, Messenger | 10 | 2003 | 2552 | 0.130 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 1997 | 130 | 0.130 |
Why?
| Genes, erbB-1 | 1 | 2016 | 17 | 0.130 |
Why?
| Education, Graduate | 1 | 2015 | 29 | 0.130 |
Why?
| Skin Neoplasms | 2 | 2013 | 756 | 0.130 |
Why?
| Drug Discovery | 1 | 2016 | 123 | 0.130 |
Why?
| Oligonucleotide Array Sequence Analysis | 3 | 2015 | 740 | 0.130 |
Why?
| Peptides, Cyclic | 1 | 1997 | 253 | 0.130 |
Why?
| HT29 Cells | 2 | 2018 | 35 | 0.130 |
Why?
| Tumor Protein p73 | 1 | 2015 | 14 | 0.120 |
Why?
| Proteasome Endopeptidase Complex | 2 | 2013 | 133 | 0.120 |
Why?
| Neoplasm Invasiveness | 3 | 2018 | 442 | 0.120 |
Why?
| Computational Biology | 2 | 2016 | 530 | 0.120 |
Why?
| Phosphoproteins | 1 | 2017 | 298 | 0.120 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2014 | 278 | 0.120 |
Why?
| Case-Control Studies | 2 | 2018 | 3003 | 0.120 |
Why?
| Luteinizing Hormone | 8 | 1993 | 169 | 0.120 |
Why?
| Testosterone | 2 | 1997 | 343 | 0.120 |
Why?
| Cluster Analysis | 2 | 2012 | 455 | 0.110 |
Why?
| Phosphorylation | 5 | 2019 | 1569 | 0.110 |
Why?
| Phenotype | 3 | 2018 | 2796 | 0.110 |
Why?
| Genotype | 1 | 2018 | 1760 | 0.110 |
Why?
| Protein Kinases | 1 | 2015 | 307 | 0.110 |
Why?
| Protein-Tyrosine Kinases | 1 | 2017 | 395 | 0.110 |
Why?
| Receptor, Insulin | 1 | 2013 | 93 | 0.110 |
Why?
| Mitochondria | 1 | 2018 | 747 | 0.110 |
Why?
| Cell Survival | 4 | 2019 | 1021 | 0.110 |
Why?
| Ubiquitin-Conjugating Enzymes | 1 | 2013 | 9 | 0.110 |
Why?
| Rats | 21 | 2004 | 4958 | 0.110 |
Why?
| Tumor Stem Cell Assay | 1 | 2012 | 33 | 0.100 |
Why?
| Aurora Kinases | 1 | 2012 | 28 | 0.100 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 57 | 0.100 |
Why?
| Alcohol Oxidoreductases | 1 | 2013 | 38 | 0.100 |
Why?
| Cyclosporine | 1 | 2013 | 161 | 0.100 |
Why?
| BRCA1 Protein | 1 | 2013 | 56 | 0.100 |
Why?
| Proto-Oncogene Proteins c-ets | 4 | 2011 | 51 | 0.100 |
Why?
| MicroRNAs | 1 | 2018 | 600 | 0.100 |
Why?
| Positron-Emission Tomography | 2 | 2011 | 259 | 0.100 |
Why?
| Receptor, ErbB-2 | 2 | 2012 | 300 | 0.100 |
Why?
| Genes, p53 | 1 | 2012 | 61 | 0.100 |
Why?
| TOR Serine-Threonine Kinases | 1 | 2014 | 358 | 0.100 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2012 | 67 | 0.100 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2013 | 139 | 0.100 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2018 | 1879 | 0.090 |
Why?
| Cellular Senescence | 1 | 2012 | 152 | 0.090 |
Why?
| Drug Screening Assays, Antitumor | 4 | 2016 | 180 | 0.090 |
Why?
| Proteasome Inhibitors | 1 | 2011 | 40 | 0.090 |
Why?
| Mammary Glands, Human | 1 | 2011 | 60 | 0.090 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 226 | 0.090 |
Why?
| Transcriptional Activation | 2 | 2003 | 337 | 0.090 |
Why?
| Cell Movement | 3 | 2011 | 868 | 0.090 |
Why?
| Cytoplasm | 1 | 2011 | 255 | 0.090 |
Why?
| Recombinant Fusion Proteins | 2 | 2011 | 616 | 0.090 |
Why?
| Protease Inhibitors | 1 | 2011 | 97 | 0.090 |
Why?
| Neoplasm Transplantation | 3 | 2016 | 228 | 0.080 |
Why?
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2009 | 6 | 0.080 |
Why?
| Ki-67 Antigen | 1 | 2010 | 103 | 0.080 |
Why?
| Capillary Permeability | 1 | 2010 | 139 | 0.080 |
Why?
| Adenocarcinoma | 1 | 2016 | 795 | 0.080 |
Why?
| Carcinoma, Hepatocellular | 1 | 2011 | 211 | 0.080 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 66 | 0.080 |
Why?
| Gastrointestinal Neoplasms | 1 | 2009 | 59 | 0.080 |
Why?
| Cell Line | 4 | 2012 | 2636 | 0.080 |
Why?
| Promoter Regions, Genetic | 3 | 2004 | 1131 | 0.080 |
Why?
| Quinazolines | 1 | 2009 | 240 | 0.070 |
Why?
| Algorithms | 2 | 2015 | 1468 | 0.070 |
Why?
| Prognosis | 2 | 2017 | 3329 | 0.070 |
Why?
| Peptide Fragments | 1 | 2011 | 666 | 0.070 |
Why?
| Drug Delivery Systems | 1 | 2010 | 296 | 0.070 |
Why?
| Enzyme Inhibitors | 3 | 2013 | 750 | 0.070 |
Why?
| Pituitary Gland, Anterior | 4 | 1992 | 39 | 0.070 |
Why?
| Disease Models, Animal | 2 | 2014 | 3532 | 0.070 |
Why?
| Colonic Neoplasms | 1 | 2009 | 215 | 0.070 |
Why?
| Reproducibility of Results | 2 | 2010 | 2763 | 0.070 |
Why?
| Proto-Oncogene Protein c-ets-1 | 2 | 2003 | 18 | 0.070 |
Why?
| Male | 25 | 2020 | 55583 | 0.060 |
Why?
| Growth Hormone-Releasing Hormone | 2 | 1997 | 26 | 0.060 |
Why?
| Rats, Inbred Strains | 12 | 1992 | 362 | 0.060 |
Why?
| Transplantation, Heterologous | 2 | 2016 | 181 | 0.060 |
Why?
| Oncogene Protein p65(gag-jun) | 1 | 2004 | 2 | 0.060 |
Why?
| Gene Expression Regulation | 2 | 2004 | 2319 | 0.060 |
Why?
| Proto-Oncogene Proteins c-jun | 1 | 2004 | 47 | 0.060 |
Why?
| Pancreatic Neoplasms | 1 | 2011 | 731 | 0.060 |
Why?
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 439 | 0.060 |
Why?
| Disease Progression | 3 | 2018 | 2380 | 0.060 |
Why?
| Transfection | 2 | 2003 | 866 | 0.060 |
Why?
| Lung Neoplasms | 1 | 2016 | 2177 | 0.050 |
Why?
| Middle Aged | 6 | 2020 | 26733 | 0.050 |
Why?
| Transcription Factor Pit-1 | 1 | 2003 | 24 | 0.050 |
Why?
| Suppression, Genetic | 1 | 2003 | 23 | 0.050 |
Why?
| Mesoderm | 1 | 2004 | 138 | 0.050 |
Why?
| Genes, Dominant | 1 | 2003 | 94 | 0.050 |
Why?
| Aged | 5 | 2020 | 19069 | 0.050 |
Why?
| Histone Deacetylase 1 | 1 | 2022 | 16 | 0.050 |
Why?
| DNA Repair | 2 | 2013 | 184 | 0.050 |
Why?
| Caspase 3 | 2 | 2013 | 235 | 0.050 |
Why?
| DNA Damage | 2 | 2013 | 351 | 0.050 |
Why?
| Acetylation | 1 | 2022 | 211 | 0.050 |
Why?
| Blotting, Northern | 3 | 1997 | 193 | 0.050 |
Why?
| Repressor Proteins | 1 | 2004 | 366 | 0.050 |
Why?
| Radioimmunoassay | 8 | 1993 | 162 | 0.040 |
Why?
| Histone Deacetylases | 1 | 2022 | 195 | 0.040 |
Why?
| Bortezomib | 2 | 2011 | 41 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 55 | 0.040 |
Why?
| Maximum Tolerated Dose | 1 | 2020 | 183 | 0.040 |
Why?
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2020 | 96 | 0.040 |
Why?
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2019 | 22 | 0.040 |
Why?
| Blotting, Western | 3 | 2010 | 1147 | 0.040 |
Why?
| Gene Expression | 3 | 1993 | 1421 | 0.040 |
Why?
| Lymphocytes | 2 | 1991 | 330 | 0.040 |
Why?
| Azetidines | 1 | 2018 | 31 | 0.040 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 23 | 0.040 |
Why?
| Spleen | 2 | 1991 | 487 | 0.040 |
Why?
| GTP Phosphohydrolases | 1 | 2018 | 65 | 0.040 |
Why?
| 4-Aminobenzoic Acid | 1 | 2018 | 6 | 0.040 |
Why?
| Nausea | 1 | 2018 | 101 | 0.040 |
Why?
| HCT116 Cells | 1 | 2018 | 70 | 0.040 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 797 | 0.040 |
Why?
| Orchiectomy | 4 | 1994 | 57 | 0.040 |
Why?
| Okadaic Acid | 1 | 1997 | 11 | 0.040 |
Why?
| Colforsin | 1 | 1997 | 48 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 3 | 1997 | 1842 | 0.040 |
Why?
| Piperidines | 1 | 2018 | 160 | 0.040 |
Why?
| Mutagenesis, Site-Directed | 2 | 2011 | 345 | 0.040 |
Why?
| Diarrhea | 1 | 2018 | 171 | 0.040 |
Why?
| Histones | 1 | 2022 | 535 | 0.040 |
Why?
| Tumor Burden | 1 | 2018 | 259 | 0.030 |
Why?
| Cell Differentiation | 1 | 2004 | 1700 | 0.030 |
Why?
| Treatment Outcome | 1 | 2010 | 9088 | 0.030 |
Why?
| Angiogenesis Inhibitors | 1 | 2018 | 214 | 0.030 |
Why?
| Cells, Cultured | 4 | 2013 | 3885 | 0.030 |
Why?
| Fatigue | 1 | 2018 | 294 | 0.030 |
Why?
| Ubiquitination | 1 | 2016 | 86 | 0.030 |
Why?
| Protein Isoforms | 1 | 2017 | 338 | 0.030 |
Why?
| Heterografts | 1 | 2016 | 117 | 0.030 |
Why?
| Administration, Oral | 1 | 2018 | 728 | 0.030 |
Why?
| Gene Rearrangement | 1 | 2017 | 135 | 0.030 |
Why?
| Aged, 80 and over | 2 | 2017 | 6345 | 0.030 |
Why?
| Cetuximab | 1 | 2016 | 90 | 0.030 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 107 | 0.030 |
Why?
| Camptothecin | 1 | 2016 | 96 | 0.030 |
Why?
| Polymerase Chain Reaction | 3 | 1993 | 993 | 0.030 |
Why?
| Capacity Building | 1 | 2015 | 51 | 0.030 |
Why?
| Models, Educational | 1 | 2015 | 84 | 0.030 |
Why?
| DNA Copy Number Variations | 1 | 2016 | 154 | 0.030 |
Why?
| Adult | 4 | 2018 | 30544 | 0.030 |
Why?
| Diphenylamine | 1 | 2014 | 6 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2016 | 372 | 0.030 |
Why?
| Follicle Stimulating Hormone | 2 | 1993 | 216 | 0.030 |
Why?
| Biopsy | 1 | 2018 | 1036 | 0.030 |
Why?
| Interdisciplinary Communication | 1 | 2015 | 183 | 0.030 |
Why?
| Databases, Genetic | 1 | 2015 | 206 | 0.030 |
Why?
| Neoplasm Metastasis | 1 | 2016 | 523 | 0.030 |
Why?
| Guanine | 1 | 1994 | 76 | 0.030 |
Why?
| Research Personnel | 1 | 2015 | 149 | 0.030 |
Why?
| Methyltransferases | 1 | 1994 | 61 | 0.030 |
Why?
| Mentors | 1 | 2015 | 156 | 0.030 |
Why?
| Benzamides | 1 | 2014 | 169 | 0.030 |
Why?
| Analysis of Variance | 1 | 1997 | 1226 | 0.030 |
Why?
| Gonadotropins | 1 | 1993 | 37 | 0.030 |
Why?
| Caspase 7 | 1 | 2013 | 20 | 0.030 |
Why?
| Butadienes | 1 | 2013 | 30 | 0.030 |
Why?
| MAP Kinase Kinase 2 | 1 | 2013 | 27 | 0.030 |
Why?
| Program Development | 1 | 2015 | 341 | 0.030 |
Why?
| Kinetics | 2 | 2014 | 1551 | 0.030 |
Why?
| MAP Kinase Kinase 1 | 1 | 2013 | 66 | 0.030 |
Why?
| Cell Cycle Checkpoints | 1 | 2013 | 84 | 0.030 |
Why?
| Cooperative Behavior | 1 | 2015 | 381 | 0.030 |
Why?
| Oncogene Proteins, Viral | 1 | 2013 | 20 | 0.030 |
Why?
| Molecular Sequence Data | 3 | 2011 | 2785 | 0.030 |
Why?
| Melanocytes | 1 | 2013 | 55 | 0.030 |
Why?
| Nitriles | 1 | 2013 | 149 | 0.030 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 69 | 0.030 |
Why?
| Membrane Proteins | 1 | 2018 | 1018 | 0.030 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 329 | 0.030 |
Why?
| Proto-Oncogene Proteins c-mdm2 | 1 | 2013 | 56 | 0.030 |
Why?
| Genes, Synthetic | 1 | 2012 | 14 | 0.030 |
Why?
| Precision Medicine | 1 | 2016 | 337 | 0.030 |
Why?
| Genes, Lethal | 1 | 2012 | 26 | 0.030 |
Why?
| Drug Hypersensitivity | 1 | 1993 | 83 | 0.030 |
Why?
| DNA, Neoplasm | 1 | 2013 | 157 | 0.030 |
Why?
| Mice, SCID | 1 | 2013 | 314 | 0.030 |
Why?
| Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 63 | 0.020 |
Why?
| Nuclear Export Signals | 1 | 2011 | 3 | 0.020 |
Why?
| Glycoprotein Hormones, alpha Subunit | 1 | 1991 | 22 | 0.020 |
Why?
| Nuclear Localization Signals | 1 | 2011 | 14 | 0.020 |
Why?
| Alcoholic Intoxication | 1 | 1992 | 62 | 0.020 |
Why?
| Peptide Mapping | 1 | 2011 | 60 | 0.020 |
Why?
| Calcium Signaling | 1 | 2013 | 217 | 0.020 |
Why?
| Microscopy, Fluorescence | 1 | 2013 | 396 | 0.020 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 351 | 0.020 |
Why?
| Amino Acid Motifs | 1 | 2011 | 197 | 0.020 |
Why?
| Amino Acid Substitution | 1 | 2011 | 262 | 0.020 |
Why?
| Colony-Forming Units Assay | 1 | 2010 | 88 | 0.020 |
Why?
| Hypertension | 1 | 2018 | 1056 | 0.020 |
Why?
| Protein Biosynthesis | 1 | 1992 | 385 | 0.020 |
Why?
| Transcriptome | 1 | 2015 | 725 | 0.020 |
Why?
| Culture Media, Conditioned | 1 | 2010 | 105 | 0.020 |
Why?
| Genes, ras | 1 | 2010 | 91 | 0.020 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 238 | 0.020 |
Why?
| Protein Transport | 1 | 2011 | 395 | 0.020 |
Why?
| Ligands | 1 | 2011 | 561 | 0.020 |
Why?
| Curriculum | 1 | 2015 | 819 | 0.020 |
Why?
| Gene Dosage | 1 | 2010 | 129 | 0.020 |
Why?
| Drug Combinations | 1 | 2010 | 287 | 0.020 |
Why?
| Structure-Activity Relationship | 1 | 2010 | 502 | 0.020 |
Why?
| Gene Knockdown Techniques | 1 | 2010 | 299 | 0.020 |
Why?
| Prolactinoma | 1 | 1989 | 11 | 0.020 |
Why?
| Serum Albumin | 1 | 1990 | 137 | 0.020 |
Why?
| Protein Structure, Tertiary | 1 | 2011 | 796 | 0.020 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2011 | 473 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2013 | 1629 | 0.020 |
Why?
| Cell Communication | 1 | 2010 | 279 | 0.020 |
Why?
| Follow-Up Studies | 1 | 2017 | 4411 | 0.020 |
Why?
| Rats, Sprague-Dawley | 4 | 1994 | 2218 | 0.020 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 398 | 0.020 |
Why?
| Pregnanediones | 1 | 1987 | 1 | 0.020 |
Why?
| Sulfonamides | 1 | 2011 | 445 | 0.020 |
Why?
| Amino Acid Sequence | 1 | 2011 | 1982 | 0.020 |
Why?
| Pituitary Neoplasms | 1 | 1989 | 157 | 0.020 |
Why?
| Anesthetics | 1 | 1987 | 54 | 0.020 |
Why?
| Calcium | 1 | 2013 | 1108 | 0.020 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 923 | 0.020 |
Why?
| Feasibility Studies | 1 | 2010 | 740 | 0.020 |
Why?
| Brain Chemistry | 1 | 1987 | 115 | 0.020 |
Why?
| Liver Neoplasms | 1 | 2011 | 506 | 0.020 |
Why?
| Metabolomics | 1 | 2011 | 521 | 0.020 |
Why?
| Estrogens | 1 | 1989 | 312 | 0.020 |
Why?
| Models, Biological | 1 | 2013 | 1620 | 0.020 |
Why?
| Flow Cytometry | 1 | 2009 | 1083 | 0.020 |
Why?
| Prostatic Neoplasms | 1 | 2013 | 921 | 0.020 |
Why?
| Proto-Oncogene Protein c-ets-2 | 1 | 2004 | 3 | 0.010 |
Why?
| Contact Inhibition | 1 | 2004 | 3 | 0.010 |
Why?
| Oncogene Protein p21(ras) | 1 | 2004 | 16 | 0.010 |
Why?
| Epidermal Growth Factor | 1 | 2004 | 161 | 0.010 |
Why?
| Antisense Elements (Genetics) | 1 | 2003 | 4 | 0.010 |
Why?
| Genetic Vectors | 1 | 2004 | 289 | 0.010 |
Why?
| Collagenases | 1 | 2003 | 22 | 0.010 |
Why?
| Matrix Metalloproteinase 3 | 1 | 2003 | 23 | 0.010 |
Why?
| Cytokines | 1 | 2010 | 1840 | 0.010 |
Why?
| Cell Adhesion | 1 | 2004 | 431 | 0.010 |
Why?
| Cell Division | 1 | 2004 | 758 | 0.010 |
Why?
| Trans-Activators | 1 | 2004 | 367 | 0.010 |
Why?
| HeLa Cells | 1 | 2003 | 562 | 0.010 |
Why?
| Brain | 1 | 1992 | 2371 | 0.010 |
Why?
| Potassium | 2 | 1990 | 128 | 0.010 |
Why?
| Base Sequence | 2 | 1993 | 2114 | 0.010 |
Why?
| Biological Assay | 2 | 1990 | 112 | 0.010 |
Why?
| Hypophysectomy | 2 | 1987 | 15 | 0.010 |
Why?
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 1994 | 5 | 0.010 |
Why?
| Cocarcinogenesis | 1 | 1994 | 14 | 0.010 |
Why?
| Injections, Intraperitoneal | 1 | 1994 | 99 | 0.010 |
Why?
| Rats, Mutant Strains | 1 | 1993 | 25 | 0.010 |
Why?
| Stress, Physiological | 2 | 1987 | 378 | 0.010 |
Why?
| Thyrotropin | 1 | 1994 | 99 | 0.010 |
Why?
| RNA-Directed DNA Polymerase | 1 | 1993 | 34 | 0.010 |
Why?
| Adrenocorticotropic Hormone | 1 | 1994 | 128 | 0.010 |
Why?
| Blotting, Southern | 1 | 1992 | 68 | 0.010 |
Why?
| Cyclic AMP | 1 | 1992 | 227 | 0.010 |
Why?
| Protein Kinase C | 1 | 1992 | 273 | 0.010 |
Why?
| Enzyme Activation | 1 | 1992 | 785 | 0.010 |
Why?
| RNA Splicing | 1 | 1992 | 245 | 0.010 |
Why?
| Cross Reactions | 1 | 1990 | 117 | 0.010 |
Why?
| Perfusion | 1 | 1990 | 148 | 0.010 |
Why?
| Dinoprostone | 1 | 1990 | 184 | 0.010 |
Why?
| Naloxone | 1 | 1990 | 97 | 0.010 |
Why?
| Bromocriptine | 1 | 1989 | 26 | 0.010 |
Why?
| Norepinephrine | 1 | 1990 | 201 | 0.000 |
Why?
| Chromatography, High Pressure Liquid | 1 | 1990 | 470 | 0.000 |
Why?
| Rats, Inbred F344 | 1 | 1989 | 241 | 0.000 |
Why?
| Depression, Chemical | 1 | 1987 | 22 | 0.000 |
Why?
| In Vitro Techniques | 1 | 1990 | 1016 | 0.000 |
Why?
| Urethane | 1 | 1987 | 41 | 0.000 |
Why?
| Pancreas | 1 | 1990 | 276 | 0.000 |
Why?
| Dopamine | 1 | 1990 | 236 | 0.000 |
Why?
| Molecular Weight | 1 | 1987 | 331 | 0.000 |
Why?
| Drug Administration Schedule | 1 | 1989 | 718 | 0.000 |
Why?
| Cerebral Cortex | 1 | 1990 | 380 | 0.000 |
Why?
| Ketamine | 1 | 1987 | 92 | 0.000 |
Why?
| Alcoholism | 1 | 1992 | 713 | 0.000 |
Why?
| Restraint, Physical | 1 | 1986 | 67 | 0.000 |
Why?
| DNA | 1 | 1991 | 1352 | 0.000 |
Why?
| Kidney | 1 | 1990 | 1188 | 0.000 |
Why?
| Liver | 1 | 1990 | 1637 | 0.000 |
Why?
| Lung | 1 | 1990 | 3559 | 0.000 |
Why?
|
|
Tentler's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|